Works matching IS 00099104 AND DT 2018 AND VI 191 AND IP 2
Results: 14
Immune checkpoint inhibitors: new strategies to checkmate cancer.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 133, doi. 10.1111/cei.13081
- By:
- Publication type:
- Article
Corrigendum.
- Published in:
- 2018
- Publication type:
- Correction Notice
<italic>Eppur Si Muove</italic>: ferritin is essential in modulating inflammation.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 149, doi. 10.1111/cei.13069
- By:
- Publication type:
- Article
Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 212, doi. 10.1111/cei.13068
- By:
- Publication type:
- Article
MicroRNA‐126 deficiency enhanced the activation and function of CD4<sup>+</sup>T cells by elevating IRS‐1 pathway.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 166, doi. 10.1111/cei.13067
- By:
- Publication type:
- Article
B cell tolerance to epidermal ribonuclear‐associated neo‐autoantigen <italic>in vivo</italic>.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 151, doi. 10.1111/cei.13066
- By:
- Publication type:
- Article
Truly selective primary IgM deficiency is probably very rare.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 203, doi. 10.1111/cei.13065
- By:
- Publication type:
- Article
Whole genome microarray expression analysis in blood identifies pathways linked to signs and symptoms of a patient with hypercalprotectinaemia and hyperzincaemia.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 240, doi. 10.1111/cei.13064
- By:
- Publication type:
- Article
A comparison of TRECs and flow cytometry for naive T cell quantification.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 198, doi. 10.1111/cei.13062
- By:
- Publication type:
- Article
The anti‐CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6‐month, open‐label Phase I clinical trial.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 229, doi. 10.1111/cei.13061
- By:
- Publication type:
- Article
<italic>In‐vitro</italic> effect of pembrolizumab on different T regulatory cell subsets.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 189, doi. 10.1111/cei.13060
- By:
- Publication type:
- Article
Alterations in circulating lymphoid cell populations in systemic small vessel vasculitis are non‐specific manifestations of renal injury.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 180, doi. 10.1111/cei.13058
- By:
- Publication type:
- Article
H‐ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 220, doi. 10.1111/cei.13057
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 1, doi. 10.1111/cei.13168
- Publication type:
- Article